Please use this identifier to cite or link to this item:
Title: Hormone Targets for the Treatment of Sleep Disorders in Postmenopausal Women with Schizophrenia: A Narrative Review
Author: González Rodríguez, Alexandre
Haba Rubio, José
Usall i Rodié, Judith
Natividad, Mentxu
Soria, Virginia
Labad, Javier
Monreal, José Antonio
Keywords: Trastorns del son
Sleep disorders
Issue Date: 15-Feb-2022
Publisher: MDPI AG
Abstract: While the early identification of insomnia in patients with schizophrenia is of clinical relevance, the use of specific compounds to treat insomnia has been studied less in postmenopausal women with schizophrenia. We aimed to explore the effects of melatonin, sex hormones, and raloxifene for the treatment of insomnia in these populations. Although melatonin treatment improved the quality and efficiency of the sleep of patients with schizophrenia, few studies have explored its use in postmenopausal women with schizophrenia. The estrogen and progesterone pathways are dysregulated in major psychiatric disorders, such as in schizophrenia. While, in the context of menopause, a high testosterone-to-estradiol ratio is associated with higher frequencies of depressive symptoms, the effects of estradiol and other sex hormones on sleep disorders in postmenopausal women with schizophrenia has not been sufficiently investigated. Raloxifene, a selective estrogen receptor modulator, has shown positive effects on sleep disorders in postmenopausal women. Future studies should investigate the effectiveness of hormonal compounds on insomnia in postmenopausal women with schizophrenia.
Note: Reproducció del document publicat a:
It is part of: Clocks & Sleep, 2022, vol. 4, num. 1, p. 52-65
Related resource:
ISSN: 2624-5175
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
clockssleep-04-00007.pdf472.39 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons